Talis Biomedical Corp
Talis Biomedical Corporation does not have significant operations. Previously, it was involved in the development of medical devices for infectious diseases and other conditions at the point of care in the United States. The company evaluates strategic alternatives, including acquisition, merger, reverse merger, divestiture of assets, a voluntary reorganization, dissolution or liquidation, and li… Read more
Talis Biomedical Corp (TLIS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: -0.233x
Based on the latest financial reports, Talis Biomedical Corp (TLIS) has a cash flow conversion efficiency ratio of -0.233x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.33 Million) by net assets ($48.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Talis Biomedical Corp - Cash Flow Conversion Efficiency Trend (2018–2023)
This chart illustrates how Talis Biomedical Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Talis Biomedical Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Talis Biomedical Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
X2M Connect Ltd
AU:X2M
|
-0.024x |
|
JET CONTRACTORS
BC:JET-CONTRACTORS
|
N/A |
|
Oxford Cannabinoid Technologies Holdings Plc
PINK:OCTHF
|
-0.001x |
|
PExA AB (publ)
F:FA0
|
-0.208x |
|
CARLSON INV. ZY 13
F:2HB
|
N/A |
|
GECI International SA
PA:ALGEC
|
-0.006x |
|
AEMLF
PINK:AEMLF
|
N/A |
|
Eastern Resources Ltd
AU:EFE
|
-0.010x |
Annual Cash Flow Conversion Efficiency for Talis Biomedical Corp (2018–2023)
The table below shows the annual cash flow conversion efficiency of Talis Biomedical Corp from 2018 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $69.12 Million | $-53.24 Million | -0.770x | +2.51% |
| 2022-12-31 | $126.74 Million | $-100.14 Million | -0.790x | -7.87% |
| 2021-12-31 | $233.98 Million | $-171.38 Million | -0.732x | -191.38% |
| 2020-12-31 | $-108.57 Million | $-87.02 Million | 0.802x | -30.34% |
| 2019-12-31 | $-21.14 Million | $-24.33 Million | 1.151x | +185.72% |
| 2018-12-31 | $-52.00 Million | $-20.94 Million | 0.403x | -- |